GB202103470D0 - Promoter - Google Patents

Promoter

Info

Publication number
GB202103470D0
GB202103470D0 GBGB2103470.7A GB202103470A GB202103470D0 GB 202103470 D0 GB202103470 D0 GB 202103470D0 GB 202103470 A GB202103470 A GB 202103470A GB 202103470 D0 GB202103470 D0 GB 202103470D0
Authority
GB
United Kingdom
Prior art keywords
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2103470.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Bristol
Syncona Investment Management Ltd
Original Assignee
University of Bristol
Syncona Investment Management Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Bristol, Syncona Investment Management Ltd filed Critical University of Bristol
Priority to GBGB2103470.7A priority Critical patent/GB202103470D0/en
Publication of GB202103470D0 publication Critical patent/GB202103470D0/en
Priority to BR112023018362A priority patent/BR112023018362A2/pt
Priority to JP2023555709A priority patent/JP2024509316A/ja
Priority to DK22710714.1T priority patent/DK4305181T3/da
Priority to CN202280034399.8A priority patent/CN117377770A/zh
Priority to MX2023010573A priority patent/MX2023010573A/es
Priority to US18/280,699 priority patent/US20250283072A1/en
Priority to AU2022235209A priority patent/AU2022235209A1/en
Priority to ES22710714T priority patent/ES3056304T3/es
Priority to KR1020237034581A priority patent/KR20230161459A/ko
Priority to EP22710714.1A priority patent/EP4305181B1/en
Priority to CA3211566A priority patent/CA3211566A1/en
Priority to EP25181596.5A priority patent/EP4722371A2/en
Priority to HRP20251561TT priority patent/HRP20251561T1/hr
Priority to IL305714A priority patent/IL305714A/en
Priority to PT227107141T priority patent/PT4305181T/pt
Priority to FIEP22710714.1T priority patent/FI4305181T3/fi
Priority to PCT/GB2022/050649 priority patent/WO2022189811A1/en
Priority to PL22710714.1T priority patent/PL4305181T3/pl
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C12N15/8645—Adeno-associated virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB2103470.7A 2021-03-12 2021-03-12 Promoter Ceased GB202103470D0 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
GBGB2103470.7A GB202103470D0 (en) 2021-03-12 2021-03-12 Promoter
PL22710714.1T PL4305181T3 (pl) 2021-03-12 2022-03-14 Minimalny promotor nefryny
ES22710714T ES3056304T3 (en) 2021-03-12 2022-03-14 Minimal nephrin promoter
EP22710714.1A EP4305181B1 (en) 2021-03-12 2022-03-14 Minimal nephrin promoter
DK22710714.1T DK4305181T3 (en) 2021-03-12 2022-03-14 Minimal nefrin-promotor
CN202280034399.8A CN117377770A (zh) 2021-03-12 2022-03-14 最小肾病蛋白启动子
MX2023010573A MX2023010573A (es) 2021-03-12 2022-03-14 Promotor minimo de nefrina.
US18/280,699 US20250283072A1 (en) 2021-03-12 2022-03-14 Minimal nephrin promoter
AU2022235209A AU2022235209A1 (en) 2021-03-12 2022-03-14 Minimal nephrin promoter
BR112023018362A BR112023018362A2 (pt) 2021-03-12 2022-03-14 Promotor mínimo de nefrina
KR1020237034581A KR20230161459A (ko) 2021-03-12 2022-03-14 최소 네프린 프로모터
JP2023555709A JP2024509316A (ja) 2021-03-12 2022-03-14 最小ネフリンプロモーター
CA3211566A CA3211566A1 (en) 2021-03-12 2022-03-14 Minimal nephrin promoter
EP25181596.5A EP4722371A2 (en) 2021-03-12 2022-03-14 Promoter
HRP20251561TT HRP20251561T1 (hr) 2021-03-12 2022-03-14 Minimalni promotor nefrina
IL305714A IL305714A (en) 2021-03-12 2022-03-14 Minimal nephrin factor
PT227107141T PT4305181T (pt) 2021-03-12 2022-03-14 Promotor mínimo de nefrina
FIEP22710714.1T FI4305181T3 (fi) 2021-03-12 2022-03-14 Minimaalinen nefriinipromoottori
PCT/GB2022/050649 WO2022189811A1 (en) 2021-03-12 2022-03-14 Minimal nephrin promoter

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2103470.7A GB202103470D0 (en) 2021-03-12 2021-03-12 Promoter

Publications (1)

Publication Number Publication Date
GB202103470D0 true GB202103470D0 (en) 2021-04-28

Family

ID=75623235

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2103470.7A Ceased GB202103470D0 (en) 2021-03-12 2021-03-12 Promoter

Country Status (18)

Country Link
US (1) US20250283072A1 (https=)
EP (2) EP4722371A2 (https=)
JP (1) JP2024509316A (https=)
KR (1) KR20230161459A (https=)
CN (1) CN117377770A (https=)
AU (1) AU2022235209A1 (https=)
BR (1) BR112023018362A2 (https=)
CA (1) CA3211566A1 (https=)
DK (1) DK4305181T3 (https=)
ES (1) ES3056304T3 (https=)
FI (1) FI4305181T3 (https=)
GB (1) GB202103470D0 (https=)
HR (1) HRP20251561T1 (https=)
IL (1) IL305714A (https=)
MX (1) MX2023010573A (https=)
PL (1) PL4305181T3 (https=)
PT (1) PT4305181T (https=)
WO (1) WO2022189811A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202003109D0 (en) * 2020-03-04 2020-04-15 Univ Bristol Gene therapy
GB202003618D0 (en) 2020-03-12 2020-04-29 Univ Bristol Gene Therapy
GB202217332D0 (en) * 2022-11-18 2023-01-04 Univ Bristol Methods
EP4397976A1 (en) * 2023-01-09 2024-07-10 x-kidney diagnostics GmbH Biomarkers for the pre-clinical and/or early-stage detection and/or diagnosis of kidney diseases
GB202309909D0 (en) * 2023-06-29 2023-08-16 Purespring Therapeutics Ltd Regulatory elements
GB202309908D0 (en) * 2023-06-29 2023-08-16 Purespring Therapeutics Ltd Polynucleotides, aav vectors, and pharmaceutical compositions for treating complement-mediated kidney diseases
GB202309913D0 (en) * 2023-06-29 2023-08-16 Purespring Therapeutics Ltd Polynucleotides, avv vectors, and pharmaceutical compositions for treating nephrotic syndrome
GB202309914D0 (en) * 2023-06-29 2023-08-16 Purespring Therapeutics Ltd Promoters

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT904392E (pt) 1996-10-17 2001-06-29 Oxford Biomedica Ltd Vectores retrovirais
US8852936B2 (en) 2012-09-21 2014-10-07 Laurantis Pharma Oy Autologous lymph node transfer in combination with VEGF-C or VEGF-D growth factor therapy to treat lymphedema and to improve reconstructive surgery
TW201506036A (zh) 2013-08-14 2015-02-16 Laurantis Pharma Oy Vegf-c及ccbe1之治療用途
GB201900702D0 (en) * 2019-01-18 2019-03-06 Univ Bristol Therapy

Also Published As

Publication number Publication date
US20250283072A1 (en) 2025-09-11
CN117377770A (zh) 2024-01-09
MX2023010573A (es) 2023-11-03
AU2022235209A1 (en) 2023-10-05
CA3211566A1 (en) 2022-09-15
IL305714A (en) 2023-11-01
KR20230161459A (ko) 2023-11-27
PL4305181T3 (pl) 2026-01-26
BR112023018362A2 (pt) 2023-12-05
ES3056304T3 (en) 2026-02-19
EP4722371A2 (en) 2026-04-08
PT4305181T (pt) 2025-12-04
HRP20251561T1 (hr) 2026-02-13
JP2024509316A (ja) 2024-02-29
FI4305181T3 (fi) 2025-12-12
EP4305181B1 (en) 2025-11-05
DK4305181T3 (en) 2025-12-15
EP4305181A1 (en) 2024-01-17
WO2022189811A1 (en) 2022-09-15

Similar Documents

Publication Publication Date Title
GB202103470D0 (en) Promoter
CA196956S (en) Onesie
DK4376213T3 (en) Antennesystem
PL4121679T3 (pl) Układ wielowężowy
GB201903499D0 (en) Minimal promoter
GB202109231D0 (en) Promoter
GB202009410D0 (en) Promoter design
GB202304841D0 (en) Promoter
GB202005473D0 (en) Forskolin-inducible promoters
GB202309914D0 (en) Promoters
EP4374847A4 (en) OBP PROMOTOR
GB202212764D0 (en) Disclosure
GB202210995D0 (en) Disclosure
GB202113569D0 (en) Disclosure
GB202113199D0 (en) Disclosure
GB202110620D0 (en) Disclosure
DK4124060T3 (en) Høreapparat
GB202109778D0 (en) Disclosure
GB202109650D0 (en) Disclosure
GB202109237D0 (en) Disclosure
CA204055S (en) Spiralizer
GB201905219D0 (en) Hypoxia-enducible promoters
GB201905220D0 (en) Forskolin-inducible promoters
GB202101496D0 (en) Disclosure
GB202101495D0 (en) Disclosure

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)